Triantafillidou Katherine, Iordanidis Fotis, Psomaderis Konstantinos, Kalimeras Eleftherios
Department of Oral and Maxillofacial Surgery, General Hospital G. Papanikolaou, Thessaloniki, Greece.
J Oral Maxillofac Surg. 2010 Oct;68(10):2489-96. doi: 10.1016/j.joms.2009.09.065. Epub 2010 Aug 1.
Acinic cell carcinoma is a rare malignant tumor of salivary glands. The purpose of this study is to evaluate the clinical outcome of acinic cell carcinoma in a group of 11 patients, who were treated in our clinic, and to discuss the management as well as the immunohistochemical features and prognosis of this carcinoma.
The study included 11 patients with acinic cell carcinoma of the minor salivary glands who were treated in our clinic. The patients were 7 women and 4 men. The patients' age ranged from 46 to 83 years. The distribution of the primary sites was buccal mucosa (4) maxilla/maxillary sinus, etc, (2), hard palate (1), junction of soft/hard palate (1), lower lip (1), labio marginal sulcus (1), and vestibular sulcus and mandible (1). All patients were treated with surgery. Adjuvant radiotherapy was used in 3 patients. Immunohistochemical assay of expression of Ki-67, p53, EGFR, and c-erbB-2/neu markers was performed on specimens of all tumors.
The mean follow-up range was 2 to 15 years. Of the 11 patients, 7 were alive (2, 3, 4, 5, and 15 years after the initial therapy). Two patients died of another cause free of the disease 9 and 10 years after the initial treatment, and 2 patients died of the disease (local recurrence, distant metastases 2 and 3 years later). Overexpression of immunohistochemical markers was evident for tumors with widespread metastases.
Acinic cell carcinoma is a rare malignant tumor of the salivary glands, characterized by an indolent clinical course with the potential for both local recurrence and distant metastases. The immunohistochemical analysis of proliferation markers provides additional prognostic information for this tumor.
腺泡细胞癌是一种罕见的唾液腺恶性肿瘤。本研究旨在评估在我们诊所接受治疗的11例腺泡细胞癌患者的临床结局,并探讨该癌症的治疗、免疫组化特征及预后。
本研究纳入了11例在我们诊所接受治疗的小唾液腺腺泡细胞癌患者。患者中女性7例,男性4例。患者年龄在46至83岁之间。原发部位分布为颊黏膜(4例)、上颌骨/上颌窦等(2例)、硬腭(1例)、软硬腭交界处(1例)、下唇(1例)、唇龈沟(1例)以及前庭沟与下颌骨(1例)。所有患者均接受了手术治疗。3例患者接受了辅助放疗。对所有肿瘤标本进行了Ki-67、p53、表皮生长因子受体(EGFR)和c-erbB-2/neu标志物表达的免疫组化检测。
平均随访时间为2至15年。11例患者中,7例存活(初始治疗后2、3、4、5和15年)。2例患者在初始治疗后9年和10年因其他原因无病死亡,2例患者死于该疾病(分别在2年和3年后局部复发、远处转移)。免疫组化标志物的过表达在有广泛转移的肿瘤中明显。
腺泡细胞癌是一种罕见的唾液腺恶性肿瘤,其临床病程较为惰性,具有局部复发和远处转移的可能性。增殖标志物的免疫组化分析为该肿瘤提供了额外的预后信息。